Tempus AI (NASDAQ:TEM) Stock: Insider David Epstein Sells 370 Shares

Tempus AI, Inc. (NASDAQ:TEM) Director David Epstein sold 370 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $74.29, for a total transaction of $27,487.30. Following the completion of the transaction, the director owned 30,474 shares of the company’s stock, valued at $2,263,913.46. The trade was a 1.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Stock Performance

Shares of Tempus AI stock opened at $70.43 on Friday. The company has a 50 day moving average of $71.21 and a 200-day moving average of $57.20. Tempus AI, Inc. has a 1-year low of $40.77 and a 1-year high of $89.09. The company has a current ratio of 2.61, a quick ratio of 3.16 and a debt-to-equity ratio of 2.70. The company has a market cap of $12.71 billion, a PE ratio of -66.44 and a beta of 3.61.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings results on Monday, November 2nd. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.16. The company had revenue of $411.54 million for the quarter, compared to analyst estimates of $409.39 million. Tempus AI had a negative return on equity of 47.00% and a negative net margin of 12.54%. The company’s revenue for the quarter was up 23.1% compared to the same quarter last year. During the same quarter last year, the company posted ($0.46) EPS. As a group, equities research analysts forecast that Tempus AI, Inc. will post -1.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. UBS Group began coverage on Tempus AI in a research report on Wednesday, September 9th. They set a “neutral” rating and a $70.00 target price on the stock. Rothschild & Co Redburn assumed coverage on Tempus AI in a research report on Tuesday, September 8th. They set a “neutral” rating and a $67.00 price target on the stock. The Goldman Sachs Group began coverage on shares of Tempus AI in a report on Monday, September 21st. They set a “neutral” rating and a $75.00 target price on the stock. Stifel Nicolaus cut their price objective on shares of Tempus AI from $60.00 to $50.00 and set a “hold” rating for the company in a research report on Monday, August 3rd. Finally, Guggenheim upped their target price on Tempus AI from $65.00 to $92.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Eleven investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Tempus AI presently has a consensus rating of “Hold” and an average target price of $79.37.

More Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Cantor Fitzgerald maintained its Buy rating, while HC Wainwright and Robert W. Baird were also reported to see strong potential appreciation. These recommendations may support investor confidence. Cantor Fitzgerald maintains Buy rating HC Wainwright forecast Baird forecast
• Positive Sentiment: Recent results were stronger than expected: Tempus reported quarterly revenue of $411.5 million, up 23.1% year over year, and earnings per share of $0.07 versus analysts’ forecast for a loss. The beat provides a favorable business-performance backdrop. Tempus AI earnings beat
• Negative Sentiment: CEO Ryan Fukushima sold 80 shares and director David Epstein sold 370 shares at $74.29. Both trades were executed under pre-arranged Rule 10b5-1 plans, and the small sales leave their substantial holdings largely intact, tempering the potential concern. Director stock sale disclosure

Hedge Funds Weigh In On Tempus AI

A number of large investors have recently added to or reduced their stakes in the business. Maryland State Retirement & Pension System boosted its position in Tempus AI by 35.5% during the 3rd quarter. Maryland State Retirement & Pension System now owns 6,649 shares of the company’s stock valued at $545,000 after buying an additional 1,743 shares during the period. Jefferies Financial Group Inc. bought a new stake in Tempus AI in the 3rd quarter worth $1,234,000. Machina Capital S.A.S. increased its position in shares of Tempus AI by 37.6% in the third quarter. Machina Capital S.A.S. now owns 11,296 shares of the company’s stock valued at $925,000 after acquiring an additional 3,085 shares during the period. Mesirow Financial Investment Management Inc. purchased a new position in shares of Tempus AI in the third quarter valued at about $210,000. Finally, Fulcrum Asset Management LLP bought a new position in shares of Tempus AI during the third quarter valued at about $420,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.